Learn More
PD-L1 (Atezolizumab) Recombinant Human Monoclonal Antibody (Atezolizumab), Functional Grade, Leinco Technologies™

Description
Specificity: Atezolizumab (RG7446; INN or code name MPDL3280A) activity is directed against PD-L1 (CD274) and B7.1 (CD80). Endotoxin Level: <1.0 EU/mg as determined by the LAL method. Purity: ≥95% monomer by analytical SEC. Preparation: Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage: Functional grade biosimilar antibodies may be stored sterile as received at 2-8C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80C. Avoid Repeated Freeze Thaw Cycles.
Specifications
Specifications
| Antigen | PD-L1 (Atezolizumab) |
| Applications | Flow Cytometry, Western Blot |
| Classification | Recombinant Monoclonal |
| Clone | Atezolizumab |
| Concentration | ≥5.0 mg/mL |
| Conjugate | Functional Grade |
| Formulation | PBS with no preservative; pH 7.2-7.4 |
| Gene Alias | MPDL3280A; RG7446; Tecentriq |
| Host Species | Human |
| Immunogen | Recombinant extracellular domain-Fc fusion of human PD-L1R |
| Show More |
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.